Source comparison
Tesamorelin Half Life: Kinetics Comparison
Understanding how tesamorelin's pharmacokinetics compare to related peptides clarifies why dosing schedules and therapeutic windows differ across growth hormone-modulating compounds. Tesamorelin 26–38 minutes 3–4 hours Once daily GHRH receptor agonist; stimula
This comparison does not assign a generated winner or score.
- Understanding how tesamorelin's pharmacokinetics compare to related peptides clarifies why dosing schedules and therapeutic windows differ across growth hormone-modulating compounds.
- Tesamorelin
- 26–38 minutes
- 3–4 hours
- Once daily
- GHRH receptor agonist; stimulates endogenous GH release from pituitary
- Visceral fat reduction in HIV lipodystrophy (FDA-approved); research into body composition
- Ipamorelin
- ~2 hours
- 2–3 hours
- 1–2 times daily
- Ghrelin receptor (GHS-R1a) agonist; stimulates GH pulse without cortisol or prolactin elevation
- Research into lean mass preservation, recovery, and metabolic function
- Sermorelin
- ~10–20 minutes
- Once daily (typically before bed)
- GHRH receptor agonist; shorter and less stable than tesamorelin
- Research into sleep-associated GH release and anti-aging protocols
- CJC-1295 (with DAC)
- 6–8 days
- Sustained elevation over days
- Once weekly
- GHRH analogue with Drug Affinity Complex; prolonged plasma stability
- Research into sustained GH elevation without daily dosing
- Exogenous GH (somatropin)
- N/A. Direct GH, not pulsatile
- Daily or multiple times daily
- Direct GH replacement; bypasses endogenous regulation
- Clinical GH deficiency; performance enhancement (off-label)
- The comparison reveals a critical insight: tesamorelin's short plasma half life does not predict therapeutic duration because it triggers a cascade, not a replacement. Peptides like CJC-1295 with DAC achieve longer circulation times through albumin binding, but the tradeoff is less physiological pulsatility. Sustained GH elevation mimics exogenous GH more than it mimics natural secretion patterns. Tesamorelin and sermorelin, despite rapid plasma clearance, preserve the pulsatile pattern that minimizes insulin resistance and other adverse metabolic effects associated with continuous GH exposure. This is why tesamorelin remains the only GHRH analogue with FDA approval for a metabolic indication. It balances efficacy with safety by working with the body's natural rhythm rather than overriding it.